Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression.


Journal

JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550

Informations de publication

Date de publication:
01 11 2022
Historique:
pubmed: 29 9 2022
medline: 5 11 2022
entrez: 28 9 2022
Statut: ppublish

Résumé

Clinical research has shown that persistent negative beliefs maintain depression and that subanesthetic ketamine infusions induce rapid antidepressant responses. To evaluate whether ketamine alters belief updating and how such cognitive effects are associated with the clinical effects of ketamine. This study used an observational case-control protocol with a mixed-effects design that nested 2 groups by 2 testing time points. Observers were not blinded. Patients with treatment-resistant depression (TRD) and healthy volunteer participants aged 34 to 68 years were included. Patients with TRD were diagnosed with major depressive disorder or bipolar depression, had a Montgomery-Åsberg Depression Rating Scale score greater than 20, a Maudsley Staging Method score greater than 7, and failed to respond to at least 2 prior antidepressant trials. Exclusion criteria were any other psychiatric, neurological, or neurosurgical comorbidities, substance use or addictive disorders, and recreational ketamine consumption. Data were collected from January to February 2019 and from May to December 2019, and data were analyzed from January 2020 to July 2021. Patients with TRD were observed 24 hours before single ketamine infusion, 4 hours after the infusion, and 4 hours after the third infusion, which was 1 week after the first infusion. Healthy control participants were observed twice 1 week apart without ketamine exposure. Montgomery-Åsberg Depression Rating Scale score and belief updating after belief updating when patients received good news and bad news measured by a cognitive belief-updating task and mathematically formalized by a computational reinforcement learning model. Of 56 included participants, 29 (52%) were male, and the mean (SEM) age was 52.3 (1.2) years. A total of 26 patients with TRD and 30 control participants were included. A significant group × testing time point × news valence interaction showed that patients with TRD updated their beliefs more after good than bad news following a single ketamine infusion (controlled for age and education: β = -0.91; 95% CI, -1.58 to -0.24; t216 = -2.67; P = .008) than controls. Computational modeling showed that this effect was associated with asymmetrical learning rates (LRs) after ketamine treatment (good news LRs after ketamine, 0.51 [SEM, 0.04]; bad news LRs after ketamine 0.36 [SEM, 0.03], t25 = 3.8; P < .001) and partially mediated early antidepressant responses (path a*b: β = -1.00 [SEM, 0.66]; t26 = -1.53; z = -1.98; P = .04). These findings provide novel insights into the cognitive mechanisms of the action of ketamine in patients with TRD, with promising perspectives for augmented psychotherapy for individuals with mood disorders.

Identifiants

pubmed: 36169969
pii: 2796906
doi: 10.1001/jamapsychiatry.2022.2996
pmc: PMC9520441
doi:

Substances chimiques

Ketamine 690G0D6V8H
Antidepressive Agents 0

Types de publication

Observational Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1124-1132

Auteurs

Hugo Bottemanne (H)

Control-Interoception Attention Team, Paris Brain Institute, Sorbonne University, National Institute of Health and Medical Research, French National Centre for Scientific Research, Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, DMU Neuroscience, Paris, France.
Department of Psychiatry, Pitié-Salpêtrière Hospital, DMU Neuroscience, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Paris, France.
Department of Philosophy, Sorbonne University, SND Research Unit, UMR 8011, Paris, France.

Orphee Morlaas (O)

Control-Interoception Attention Team, Paris Brain Institute, Sorbonne University, National Institute of Health and Medical Research, French National Centre for Scientific Research, Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, DMU Neuroscience, Paris, France.

Anne Claret (A)

Department of Psychiatry, Pitié-Salpêtrière Hospital, DMU Neuroscience, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Paris, France.

Tali Sharot (T)

Affective Brain Lab, Department of Experimental Psychology, University College London, London, United Kingdom.
Max Planck UCL Centre for Computational Psychiatry and Ageing Research, London, United Kingdom.
Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge.

Philippe Fossati (P)

Control-Interoception Attention Team, Paris Brain Institute, Sorbonne University, National Institute of Health and Medical Research, French National Centre for Scientific Research, Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, DMU Neuroscience, Paris, France.
Department of Psychiatry, Pitié-Salpêtrière Hospital, DMU Neuroscience, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Paris, France.

Liane Schmidt (L)

Control-Interoception Attention Team, Paris Brain Institute, Sorbonne University, National Institute of Health and Medical Research, French National Centre for Scientific Research, Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, DMU Neuroscience, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH